Project Grant R01CA301356
Award Date 6/1/26
Completion Date 5/31/31
Dollars Obligated $674K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $391,826 to the University of Pennsylvania on July 16, 2025, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate an innovative nanoparticle-based therapeutic platform for breast cancer treatment. The project, which extends through June 30, 2027, focuses on designing biodegradable polyphosphazene nanoparticles (PPNPs) that combine heat shock protein (HSP) inhibitor drug...
- Federal Grant Award Summary The University of Pennsylvania received a $657,168 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on August 18, 2025, to support clinical translation of JAS239, a choline-targeted near-infrared (NIR) fluorophore designed to improve surgical outcomes in lung cancer resection. The project, extending through July 31, 2030, will deliver investigational new drug (IND)-enabling preclinical...
- Federal Grant Award Summary The University of Pennsylvania received a $415,623 Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) for the period April 16, 2026, through March 31, 2028. The project develops and demonstrates a low-cost, continuous-flow hyperpolarized agent production device capable of generating magnetic resonance imaging (MRI) contrast agents at tracer concentrations suitable for continuous infusion. This...
- Federal Grant Award Summary The University of Pennsylvania received a $625,756 Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394), effective August 12, 2025 through July 31, 2028. This award supports development of BDEVS (Bead-based Digital Single Molecule-Single Extracellular Vesicle Sorting), a high-throughput microfluidic platform designed to advance early cancer detection through ultra-sensitive profiling of...
- Federal Grant Award Summary The National Cancer Institute awarded a $122,610 Project Grant to the University of Pennsylvania on August 11, 2025, under the Cancer Treatment Research program (CFDA 93.395). The award, with a completion date of July 31, 2030, supports the development of a system to advance National Cancer Institute (NCI)-sponsored clinical trials for patients with rare gastrointestinal malignancies and rare disease populations. The project leverages the principal investigator's...
- Federal Project Grant Summary The University of Pennsylvania received a $109,076 Project Grant awarded on January 30, 2026, by the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) to support biomedical research training and career development in cancer research. The grant funds a research project titled "Exploring Metabolic Crosstalk Between Cancer Cells and Neutrophils in Pancreatic Ductal Adenocarcinoma," with completion scheduled for July 29,...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The University of Pennsylvania $178,893.00 under the Cancer Treatment Research program (CFDA 93.395) as a Project Grant effective September 1, 2025, through August 31, 2030. The award supports Dr. Naomi Haas's initiatives to develop and advance immunotherapy clinical trials in renal cell cancer (RCC) for potential integration into the National Clinical Trials Network (NCTN). As a genitourinary medical oncologist and Renal...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pennsylvania a $100,228 Project Grant under the Cancer Research Manpower program (CFDA 93.398) on December 1, 2026, with a completion date of April 30, 2029. This award supports research training and career development activities focused on identifying immune mediators in BRCA1/2-deficient high-grade serous ovarian cancer (HGSOC). The project aims to elucidate the mechanisms driving immune...
- Federal Grant Award Summary The University of Pennsylvania received a $434,969 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) beginning May 1, 2026, and concluding April 30, 2031. This five-year research project investigates the cellular mechanisms underlying FLT3-mutant acute myeloid leukemia (AML) persistence during targeted therapy with FLT3 inhibitors. The research delivers fundamental mechanistic insights through an...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Pennsylvania a $703,071 Project Grant on April 10, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct research on the determinants of long-term CAR-T (chimeric antigen receptor T cell) cell persistence in blood cancer patients. The research will define the specific T cell characteristics and clones responsible for durable remissions in CAR-T cell therapy, with particular focus on...